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Early identification and referral of people with CKD has the
potential to reverse, delay, or prevent progression of disease
and is a key focus of international initiatives in the area of
kidney disease. The goals of early identification and referral
are several-fold and include:
1. Provision of specific therapy based on diagnosis
2. Slowing/arresting CKD progression
3. Evaluation and management of comorbid conditions
4. Prevention and management of CVD
5. Identification, prevention, and management of CKD-
specific complications (e.g., malnutrition, anemia, bone
disease, acidosis)
6. Planning and preparation for RRT (e.g., choice of
modality, access-placement and care, preemptive trans-
plantation)
7. Psychosocial support and provision of conservative care
and palliative care options where required
5.1: REFERRAL TO SPECIALIST SERVICES
5.1.1: We recommend referral to specialist kidney care
services for people with CKD in the following
circumstances (1B):
K AKI or abrupt sustained fall in GFR;
K GFR o30ml/min/1.73 m2 (GFR categories
G4-G5)*;
K a consistent finding of significant albuminuria
(ACR Z300mg/g [Z30mg/mmol] or AER
Z300mg/24 hours, approximately equivalent
to PCR Z500mg/g [Z50mg/mmol] or PER
Z500mg/24 hours);
K progression of CKD (see Recommendation
2.1.3 for definition);
K urinary red cell casts, RBC 420 per high
power field sustained and not readily
explained;
K CKD and hypertension refractory to treatment
with 4 or more antihypertensive agents;
K persistent abnormalities of serum potassium;
K recurrent or extensive nephrolithiasis;
K hereditary kidney disease.
5.1.2: We recommend timely referral for planning renal
replacement therapy (RRT) in people with pro-
gressive CKD in whom the risk of kidney failure
within 1 year is 10-20% or higherw, as determined
by validated risk prediction tools. (1B)
RATIONALE
This statement reminds the practitioner that there is a need
for timely referral for RRT planning in order to ensure good
decision making and outcomes. The use of the word ‘timely’
is vague as this is not yet determined, and is based on patient
and system factors. The actual amount of time required at a
minimum is at least 1 year to ensure appropriate education,
understanding and referrals to other practitioners (e.g.,
vascular access surgeons, transplant teams, etc). The second
part of the statement refers to the fact that those who are
progressing (versus those who are stable) are the ones who
will benefit from this referral. Hence, there is a need to apply
prediction tools to help identify the risk of progression. We
have not stated which prediction tool is preferred as these
may differ depending on information available in any
individual or local experience. Examples of prediction tools
can be found in recent publications.257,260,261
The scope of nephrology practice includes a wide variety
of conditions including not only ESRD but also acute and
chronic primary and systemic diseases involving individual
elements of the kidney, resistant hypertension, and biochem-
ical derangements. There are thus more potential benefits of
nephrology referral than those widely recognized such as
identification of reversible causes of CKD, provision of
treatment that may slow progression of CKD, management of
the metabolic complications of advanced CKD, and prepara-
tion for dialysis and transplantation.
In certain people, such as those with diabetes, transition to a
severe reduction in GFR and kidney failure may progress rapidly.
In such individuals early nephrology referral is the watchword
but when an individual’s kidney function is relatively stable (rate
of decline in GFR o5ml/min/1.73 m2/year), we suggest using
the grid as a guide (Figure 21). Where refer is marked by an
asterisk, referring clinicians may wish to discuss with their
nephrology service depending on local arrangements.
Evidence Base
Although referral recommendations in the literature are
inconsistent, criteria for nephrology referral include SCr or
GFR, proteinuria, hematuria, BP, and electrolyte derange-
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*If this is a stable isolated finding, formal referral (i.e., formal consultation
and ongoing care management) may not be necessary and advice from
specialist services may be all that is required to facilitate best care for the
patients. This will be health-care system dependent.
wThe aim is to avoid late referral, defined here as referral to specialist services
less than 1 year before start of RRT.
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ment.670 Data relating to referral for those with glomerular
disease, hypertension, AKI, and diabetes may be found in the
relevant guidelines.7,8,10,262
In this section we will briefly consider summaries of the
evidence relating to timely referral for planning RRT in
people with progressive CKD. In this aspect the literature
concerning late referral in the last quarter of a century has
been remarkably consistent; both studies and narrative
reviews identifying a number of adverse consequences of
late referral and related benefits of early referral (Table 35).
Patients who are aged 475 years, female, non-Caucasian,
uninsured, of lower socioeconomic or educational status, or
have multiple comorbidities are most at risk for non-referral
for CKD care.671,672 Patients with kidney disease have never
been randomized to early or late referral to nephrology
services and the definition of late referral in the published
studies varies; three months is probably less than the absolute
minimum amount of time required for assessment, education,
preparation for RRT and creation of access but is the most
frequently employed definition. Overall there are more than 50
studies in the published literature and a meta-analysis of 22 of
these studies from 10 different countries serves to underline
some of the key messages (Table 36), giving an indication of
the size of the differences in mortality and hospital length of
stay and also highlighting the significantly lower serum
albumin level in late referred patients.673
A systematic review considered twenty-seven longitudinal
cohort studies providing data on 17,646 participants of
whom 11,734 were referred early and 5912 (33%) were
referred late.674 OR for mortality reductions in patients
referred early were evident at 3 months (OR 0.51; 95% CI
0.44-0.59; Po0.0001) and remained significant at 5 years
(OR 0.45; 95% CI 0.38-0.53; Po0.0001). Initial hospitaliza-
tion was 8.8 days shorter with early referral (95% CI -10.7 to
-7.0 days; Po0.0001). Differences in mortality and hospita-
lization data between the 2 groups were not explained by
differences in prevalence of diabetes mellitus, previous CAD,
BP control, serum phosphate, and serum albumin. Early
referral was associated with better preparation and earlier
placement of dialysis access and better uptake of peritoneal
dialysis.
Over a decade ago McLaughlin et al. evaluated the cost
implications of early versus late referral.675 Outcomes of
interest were total cost of patient care, patient life-years,
patient life-years free of RRT and hospital length of stay.
Mean total costs per patient over five years were US$87,711
and US$110,056 for early and late referrals, respectively. The
mean patient life-years were 3.53 and 3.36 years, respectively,
and the patient life-years free of RRT were 2.18 and 1.76
years, respectively. Those patients referred early spent
significantly less time in hospital (length of stay 25 days
versus 41 days). Klebe et al. subsequently investigated the
annualized cost of implementation of referral guidelines for
CKD.676 Although CKD guideline implementation resulted
in significant increases in nephrology referral and additional
investigation, they estimated that the associated costs could
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Figure 21 |Referral decision making by GFR and albuminuria. *Referring clinicians may wish to discuss with their nephrology service
depending on local arrangements regarding monitoring or referring. GFR, glomerular filtration rate. Modified with permission from
Macmillan Publishers Ltd: Kidney International. Levey AS, de Jong PE, Coresh J, et al.30 The definition, classification, and prognosis of chronic
kidney disease: a KDIGO controversies conference report. Kidney Int 2011; 80: 17-28; accessed http://www.nature.com/ki/journal/v80/n1/
full/ki2010483a.html
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be recouped by delaying dialysis requirement by 1 year in one
individual per 10,000 patients managed according to guide-
lines.
International Relevance
Local practice and resource will dictate local referral practice
but regardless of the health-care system, delay or prevention
of progression of both CKD and complications associated
with CKD will add value. Local organizations will determine
the best methods of communication and interaction between
patients, specialists, and primary care physicians.
Implications for Clinical Practice and Public Policy
Implementation of referral guidelines will inevitably lead to
an increased workload for specialist nephrology services.
However, introduction of local initiatives in conjunction with
primary care providers can improve the appropriateness and
quality of the referral. Local initiatives combined with
national policy and practice changes can lead to an
improvement in the outcomes of CKD patients regardless
of the level of resource available.
Pediatric Considerations
Current pediatric practice in most areas of the world would
suggest a higher level of kidney function for referral than that
for adults, though the principles remain the same. Much of
the pediatric nephrologist’s consultation occurs from infants,
or even antenatal sources, where the identification of the
child as being ‘at-risk’ may be apparent from radiographic
studies performed in utero. The relatively non-specific signs
and symptoms of most forms of renal disease in the young
child mandates a higher level of suspicion in the referring
physician, and a lower threshold of acceptance of the consult
in the subspecialty clinic accepting these referrals.
Attempts to develop universal guidelines for referral
of children to pediatric nephrology services would be
dependent on local resources (as is the case for adults) and
it is of value to consider in broad categories the types of
conditions for which referral to a pediatric nephrologist
would be expected to provide benefit to the referring
physician and patient/family.
In a recent review Barakat677 attempts to address a
number of these issues by outlining the most common
presentations of a child with significant renal disorders.
Barakat and Chesney also suggest a number of specific areas
in terms of initial investigations, management, and follow-up
where the primary care physician can legitimately play a role
in the care of the child with renal disease and provides a list
of suggested referral triggers.678
While there will be variation in referral triggers, referral
would be recommended for the following: acute or chronic
reduction in renal function, poorly treated or severe
hypertension, severe electrolyte abnormalities, the finding
of significant abnormalities in urinary tract structure, or the
presence of systemic diseases likely to produce renal effects.
Similarly, the need for education in progressive conditions,
performance of and interpretation of renal biopsies, and
allaying parental/patient anxiety would also be acceptable
reasons for referral.
There is no ‘minimum acceptable value’ of renal
dysfunction below which one can be certain to see significant
abnormalities in clearance, electrolyte, or other side effects
associated with progressive renal disease in children such as
growth failure or neurocognitive issues. However, the
Table 35 | Early versus late referral: consequences and benefits
Consequences of late referral Benefits of early referral
Anemia and bone disease Delay need to initiate RRT
Severe hypertension and fluid overload Increased proportion with permanent access
Low prevalence of permanent access Greater choice of treatment options
Delayed referral for transplant Reduced need for urgent dialysis
Higher initial hospitalization rate Reduced hospital length of stay and costs
Higher 1-year mortality rate Improved nutritional status
Less patient choice of RRT modality Better management of CVD and comorbid conditions
Worse psychosocial adjustment Improved patient survival
Abbreviations: CVD, cardiovascular disease; RRT, renal replacement therapy.
Table 36 |Outcomes of early versus late referral
Variable Early referral mean (SD) Late referral mean (SD) P value
Overall mortality, % 11 (3) 23 (4) o0.0001
1-year mortality, % 13 (4) 29 (5) 0.028
Hospital length of stay, days 13.5 (2.2) 25.3 (3.8) 0.0007
Serum albumin at RRT start, g/dl [g/l] 3.62 (0.05) [36.2 (0.5)] 3.40 (0.03) [34.0 (0.3)] 0.001
Hematocrit at RRT start, % 30.54 (0.18) 29.71 (0.10) 0.013
Abbreviation: RRT, renal replacement therapy.
Adapted from Am J Med, Chan MR, Dall AT, Fletcher KE, et al.673 Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. 120:
1063-1070, 2007, with permission from Elsevier; accessed http://download.journals.elsevierhealth.com/pdfs/journals/0002-9343/PIIS000293430700664X.pdf
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KDOQI CKD Guidelines1 stated that while a child with a
eGFR o30ml/min/1.73 m2 warranted referral to a pediatric
nephrologist in all cases, that in fact it was also reasonable to
consider any child with evidence of CKD– and in particular
those with eGFR o60ml/min/1.73 m2 – for referral to a
pediatric nephrologist regarding evaluation and manage-
ment.43
It is reasonable to presume that, as in adults, the concept
of referral ‘early’ or ‘above’ some minimum level of function
should allow for numerous benefits to the patient and family,
but again there are few data for this in children. The most
informative information on both of these issues can be
derived from two papers examining the issue of late referrals
of children who eventually required ESRD care. Kennedy
et al.679 demonstrated that at the time of referral to their
center, the children 41 year of age had a median Schwartz
eGFR of only 27 (IQR 9-52) ml/min/1.73 m2, and in fact 55%
of these children over the age of 1 year were referred with an
eGFR o30ml/min/1.73 m2, meeting one of two definitions
of a late referral. When they considered their second
definition of initiation of RRT within 90 days of referral,
commonly used in the literature for this particular topic,
30% of the eligible cohort required RRT within that 90-day
window and hence were considered late referrals on this
basis. The potential effect on the child’s health could be
ascribed to such a delay in referral: those children had
lower mean Hb (8.7± 0.6 g/dl [87± 6 g/l]) versus (12.8±
0.6 g/dl [128 ± 6 g/l]) and higher median urea (34 (IQR
5-14) mmol/l [203 (IQR 30-84) mg/dl] versus 6 (IQR 5-14)
mmol/l [36 (IQR 30-84) mg/dl], Po0.001) than those who
presented with eGFR 430ml/min/1.73 m2. Secondary
analysis confirmed this was also true in the groups if one
looked at those above or below an eGFR of 60ml/min/
1.73 m2. The second paper by Boehm and colleagues680 was a
retrospective single pediatric center report that demonstrated
that over B30 years of referrals (N ¼ 111), 24% of them
could be considered as late referrals, as defined by need for
RRT within 90 days of referral. In this late referral group, the
eGFR (Schwartz) was significantly lower than those present-
ing later, (14.9 versus 34.2ml/min/1.73 m2, Po0.001) as was
the Hb at presentation (8.0 g/dl [80 g/l] versus 10.5± 2.3 g/
dl [105 ± 23 g/l]; Po0.001). Importantly the Hb deficit
persisted at the time of RRT initiation, with the Hb in the late
referral group being 8.5 g/dl [85 g/l] versus 9.8± 1.9 g/dl [98
± 19 g/l] in the earlier referred patients, Po0.01. The other
metric of interest chosen by these authors to evaluate the
possible detrimental effect of late referral was the likelihood
of a given child having a pre-emptive transplant, i.e., prior to
dialysis initiation. While this association was not confirmed
in Kennedy’s paper, Boehm and his group demonstrated that
in their patient population children who were referred late
only 11% were preemptively transplanted as compared to
40% of children who presented to care more than 90 days
prior to the need for some form of RRT. Of further interest,
although somewhat counterintuitive, the proportion of
patients in the Boehm study who initiated hemodialysis
was not statistically different between those in the late versus
early referral groups, 62% versus 67%, Po0.05 respectively.
The underlying concept of referral to a pediatric
nephrologist in the face of rapid progression of renal failure
is of course applicable in full. However, no current validated
risk of progression tool exists in pediatric nephrology. As to
what level of functional decline might be considered
‘concerning,’ the best evidence is derived from the long-
itudinal iohexol GFR data as accrued in the CKiD trial. Data
from that study related to the annualized rate of decline in
renal function for children with glomerular conditions is
10.5% as compared to those with a non-glomerular causes
in whom the annualized rate of change is only 3.9%.71 Any
child whose rate of decline exceeded these two values would at
least warrant much closer follow-up and/or investigation for
modifiable factors to slow progression. Note this is not to say
these rates of decline should be considered to be ‘normal’ for
either category. All efforts to slow decline in renal function
would still be of vital importance in every individual.
5.2: CARE OF THE PATIENT WITH PROGRESSIVE CKD
The following section describes recommended structures and
key milestones for people with progressive CKD. The
recommendations are intended to model best practices but
it is appreciated that different health-care systems, geogra-
phical issues, and economic considerations will have variable
abilities to implement these recommendations.
Key aspects of caring for people with progressive CKD, as
they approach end of life or RRToptions are addressed in this
section.
5.2.1: We suggest that people with progressive CKD should
be managed in a multidisciplinary care setting. (2B)
5.2.2: The multidisciplinary team should include or have
access to dietary counseling, education and counsel-
ing about different RRT modalities, transplant
options, vascular access surgery, and ethical, psy-
chological, and social care. (Not Graded)
RATIONALE
Optimal care is that care which leads to the best outcomes for
the individual, the population, and society. The model of care
varies according to CKD severity, which will determine the
target population and goals. These statements are worded to
predominantly encompass those people likely to progress to
ESRD. CKD models of care follow the same principles
embodied in the chronic disease model of care (Figure 22).
The specific components for CKD models of care include:
protocols for laboratory and clinic visits; attention to
cardiovascular comorbidities and CKD-associated comorbid-
ities such as anemia; a vaccination program (see Recommen-
dation 4.6.1-4.6.6); an education program which includes
both general CKD and RRT education (including conserva-
tive management where appropriate); self-management;
lifestyle modification including diet, exercise, and smoking
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cessation; and counseling and support for factors such as
social bereavement, depression, and anxiety.
International Relevance
Standardized and culturally appropriate protocols should be
considered. While it is recognized that resources may vary across
and within jurisdictions, recommendations here are based on
principles of care, which should be relevant across the globe.
Implications for Clinical Practice and Public Policy
CKD is a complex condition and co-exists with many other
conditions. Therefore models of care should be developed
that integrate the complexity of the clinical conditions
involved, patient-centered philosophies, and the health-care
environment. The principles of care are universal but
implementation may be customized to specific circum-
stances.
Pediatric Considerations
Papers addressing the need for and effectiveness in the utility
of multidisciplinary clinics for management of pediatric CKD
patients have been published. In 2012, Ajarmeh et al.682 des-
cribed a retrospective comparison of two cohorts of children
aged 0-18 years of age and followed at a single Canadian
tertiary care referral center over a 1-year time period either
before or following the full implementation of a multi-
disciplinary CKD clinic which included the services of
dedicated pediatric nephrologists, renal nursing, pharmacy,
dietitians, social workers, and a renal database manager. In
2009, Menon et al.683 published data from a large American
pediatric referral center and compared the outcomes of
children from one of two 5-year cohorts in the period
immediately preceding or following the initiation of a specific
Chronic Renal Insufficiency clinic which was staffed by
pediatric nephrologists, nurse clinicians, transplant coordi-
nators, dietitians, social workers, and a psychologist.
Ajarmeh et al.682 compared the two cohorts in a number of
areas during their year of follow-up whereas Menon et al.683
chose to look at each individual patient in the 12 months
immediately prior to initiating RRT. While the studies had
different variables of interest and used slightly different
approaches for comparison of results between their groups,
both demonstrated a reduction in the rate of decline in
estimated renal function, improved Hb levels, and improve-
ment in at least some aspect of bone mineral metabolism
control in their respective cohorts cared for in the multi-
disciplinary era. In addition, both studies also demonstrated a
decrease in resource utilization by patients in the multi-
disciplinary clinic as measured by median length of stay682 and
number of unplanned admissions per patient per year.683 Also
of note, Menon et al. demonstrated that in the patients who
initiated dialysis (which was how the cohort was chosen), more
patients who started hemodialysis did so with a functioning
arteriovenous fistula or arteriovenous graft at the time of
initiation compared to those from the general nephrology clinic
era (85.7 versus 20%, P ¼ 0.02).
5.3: TIMING THE INITIATION OF RRT
5.3.1: We suggest that dialysis be initiated when one or
more of the following are present: symptoms or
signs attributable to kidney failure (serositis, acid-
base or electrolyte abnormalities, pruritus); inability
to control volume status or blood pressure; a
progressive deterioration in nutritional status re-
fractory to dietary intervention; or cognitive im-
pairment. This often but not invariably occurs in the
GFR range between 5 and 10ml/min/1.73 m2. (2B)
5.3.2: Living donor preemptive renal transplantation in
adults should be considered when the GFR is
o20ml/min/1.73 m2, and there is evidence of
progressive and irreversible CKD over the pre-
ceding 6-12 months. (Not Graded)
RATIONALE
The statement is worded very precisely to highlight the need
for RRT to address symptoms and to avoid the institution of
dialysis therapy at an arbitrary number representing the
degree of residual renal function. Given the risks and benefits
of RRT, as well as the potential imprecision of measurements,
patients need to be treated according to symptoms and signs,
not simply based on a laboratory value.
Data from national registries has shown a consistent rise
in GFR at initiation of RRT. This rise has been driven partly
by a desire to improve nutritional status and also by earlier
observational data suggesting adverse outcomes associated
with RRT initiation at lower GFR. These early data were
subject to much confounding. RCT data, supported by large
registry-based studies corrected for confounding, show no
survival advantage to early start dialysis (Initiating Dialysis
Figure 22 |The CKD chronic care model. CKD, chronic kidney
disease. Adapted by permission from BMJ Publishing Group
Limited. Improving the quality of health-care for chronic
conditions. Epping-Jordan JE, Pruitt SD, Bengoa R, et al.681
Qual Saf Health Care. 13: 299-305, 2004; accessed
http://qualitysafety.bmj.com/content/13/4/299.full.pdf+html
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Early and Late [IDEAL] study, see Evidence Base Below).
Thus, the statement as written should help the clinician to
balance symptoms with laboratory values in decision making.
The statement regarding living donor transplantation is
intended to ensure that practitioners think about this option
in the context of the totality of RRT options. It is worded to
be concordant with local living donation transplant policies.
It aims to reflect the need for risk-benefit assessment of
preemptive renal transplantation in all individuals. Note that
the statement asks clinicians to consider this option, but does
not state at which level of GFR the preemptive transplant
would occur as this is a matter of local practice and patient-
specific considerations.
Evidence Base
The perceived survival advantage of early start of dialysis was
questioned by a study from the Netherlands Cooperative
Study on the Adequacy of Dialysis Study Group (NECO-
SAD).684 Of 253 patients with new ESRD, 94 (37%)
started dialysis late (GFR 4.9 ± 1.7ml/min/1.73 m2) and 157
started in a timely fashion (GFR 7.1±2.4ml/min/1.73 m2).
Although there was a small gain in survival time over 3 years
after start of dialysis for the timely start group (2.5 months)
there was no significant difference in survival between the
2 groups and the gain in survival time was offset by an
estimated lead-time bias of between 4.1 and 8.3 months. In a
study eliminating the effect of lead-time bias Traynor et al.
found no benefit in survival in those initiating dialysis
early.685 Subjects starting dialysis early (N¼ 119) had a
median IQR CrCl of 10.4 (9.1-11.9) ml/min versus 6.7 (5.6-
7.5) ml/min in 116 subjects starting dialysis late. After
correction for multiple confounders, they found an 11%
greater hazard for mortality with each 1ml/min increase in
CrCl at start of dialysis (HR 1.11; 95% CI 1.01-1.21;
P¼ 0.024). Subsequent observational studies, including large
dialysis registry studies from around the globe, have all
suggested increased mortality when dialysis is started
early.686–696 These studies encountered multiple difficulties
in drawing conclusions from this observational approach
including lead-time bias, problems with estimating GFR from
SCr in people with low muscle mass and/or fluid overload,
the fact that people with symptoms and/or increased
comorbidity are more likely to start dialysis early, and finally
survivor bias in studies including people only when they start
dialysis (and therefore excluding those who die prior to
starting diaysis). These confounders were largely addressed by
a multicenter controlled trial in which 828 adults with
progressive CKD and CrCl 10-15ml/min/1.73 m2 were
randomly assigned to early (CrCl 10-14ml/min [0.17-
0.23ml/s]) or late (CrCl 5-7ml/min [0.08-0.12ml/s]) initia-
tion of dialysis.697 The study protocol allowed an earlier start
where deemed clinically necessary by investigators and
although the difference in GFR at dialysis initiation between
the 2 groups was significant (early start CrCl 12.0 versus late
start 9.8ml/min, MDRD GFR 9.0 versus 7.2ml/min/
1.73 m2), it was less than planned because 19% of early
starters started late and 76% of late starters started early. There
was no difference in mortality between the early and late start
groups and no difference in the study’s secondary outcomes
(cardiovascular events, infectious events and complications of
dialysis) between the 2 groups. Finally, a further observational
study sought to examine the effect of early initiation of dialysis
on survival in a ‘healthy’ group of 81,176 subjects with ESRD
aged 20-64 years, without diabetes, and with no comorbidity
other than hypertension.698 The unadjusted 1-year mortality
by MDRD GFR at dialysis initiation ranged from 6.8% in the
reference group (GFR o5.0ml/min/1.73 m2) to 20.1% in
the highest GFR group (Z15.0ml/min/1.73 m2). In an even
healthier subset of 35,665 subjects with serum albumin
concentrations of 3.5 g/dl or higher prior to hemodialysis
initiation, the 1-year mortality was 4.7%. In this group the
adjusted HR for mortality was 1.27 for GFR 5.0-9.9ml/min/
1.73 m2, 1.53 for GFR 10.0-14.9ml/min/1.73 m2, and 2.18 for
GFR Z15.0ml/min/1.73 m2 compared with the reference
group of GFR o5.0ml/min/1.73 m2.
International Relevance
The availability of resources for formal multidisciplinary
teams, educational materials, and access to specialized
counseling for diet, advance directives, access planning, and
pre-emptive transplantation varies around the world. These
statements are proposed so that ‘best practices’ can be
documented or aspired to. The need for education, planning,
and appropriate expertise for the management of this patient
group is internationally relevant. The methods, frequency,
and tools with which this can be accomplished will be region
specific.
Implications for Clinical Practice and Public Policy
There is a need to focus on regular symptom assessment as
part of CKD review in those with lower eGFR values.
Individual assessment and availability of resources will
dictate specific timing of therapies.
Clinicians should be aware of the impact of early dialysis
start on QOL699 before recommending this strategy to
patients.
Pediatric Consideration
Timing of initiation of dialysis. As might be expected,
information as to the proper timing for initiation of dialysis
does not exist for children. Thus, it would seem reasonable to
follow the guidelines as set out for the adults. A review by
Greenbaum and Schaefer700 provides the reader with
generally agreed upon absolute and relative indications for
initiation of dialysis in the child. The absolute indications
listed are those of neurologic consequences attributable to
uremia; hypertension that fails to respond to antihyperten-
sive therapy; pulmonary edema unresponsive to diuretics;
pericarditis; bleeding tendency; and refractory nausea or
vomiting. However, the authors clearly state that there is no
current consensus as to the validity of the relative indications
and specifically the level at which each engenders the need for
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dialysis. Relative indications to commence dialysis include
less severe uremic symptoms, hyperkalemia, hyperphos-
phatemia, malnutrition, and growth failure. The authors
point out as well that the answer to ‘early’ versus ‘late’
dialysis initiation cannot be addressed in any meaningful
way in children as there is currently lack of data; and the
unique factors to consider in a child such as growth,
psychosocial development, likely renal transplant, and need
for extended time on both dialysis and in transplant make the
probability of a clinical trial to address this issue nearly
impossible.
Timing of living donor transplant. There is no direct
evidence to guide the pediatric nephrologist as to the ‘best’
timing for a living donor transplant in children. In each
individual case the relative likelihood of improvement in
presumed uremic symptoms and burden of disease as related
to management of CKD will need to be balanced against the
risks of transplant surgery itself and the attendant medication
risks with prolonged immunosuppression. While there is
little doubt as to the benefit in overall lifespan accrued by a
child who is transplanted as opposed to one maintained on
standard dialysis therapies during their childhood (average
life expectancy of 63 versus 38 years respectively),701 the issue
as to what level of residual function is sufficient to justify
delay or conversely proceeding to transplant is simply not
readily available.
It should also be noted that reliance on GFR as the sole
marker of disease intensity is unlikely to be sufficient for
making such a decision, and patient symptoms and/or
unique family factors may play a significant role in the
decision as to timing of a living donor transplant (e.g., a
young grandparent available and healthy to donate at age 60
years may not be eligible at age 63 years and so an earlier
transplant would be favored).
5.4: STRUCTURE AND PROCESS OF COMPREHENSIVE
CONSERVATIVE MANAGEMENT
5.4.1: Conservative management should be an option in
people who choose not to pursue RRT and this
should be supported by a comprehensive manage-
ment program. (Not Graded)
5.4.2: All CKD programs and care providers should be
able to deliver advance care planning for people
with a recognized need for end-of-life care,
including those people undergoing conservative
kidney care. (Not Graded)
5.4.3: Coordinated end-of-life care should be available
to people and families through either primary
care or specialist care as local circumstances
dictate. (Not Graded)
5.4.4: The comprehensive conservative management
program should include protocols for symptom
and pain management, psychological care, spiri-
tual care, and culturally sensitive care for the
dying patient and their family (whether at home,
in a hospice or a hospital setting), followed by the
provision of culturally appropriate bereavement
support. (Not Graded)
RATIONALE
These statements are intended to highlight the need for
comprehensive conservative care processes and resources in the
care of this complex patient group. There is increasing
recognition that provision of organized care to those who are
dying or choose to not pursue dialysis and transplant care is of
value to the patients and their families. Clinicians involved in
caring for these patients should be alerted to this need. These
statements are positioned so as to overtly state this need.
In different societies or cultural areas, the form
and structure of this care may vary tremendously and
families or religious organizations may be able to deliver
expert and sensitive care. The details here are listed not to be
prescriptive but rather to articulate the ‘best practices’ in
communities where resources may be available and to serve a
construct to review in those locations where resources are
more limited.
Evidence Base
The evidence base for these statements is limited to
documents describing the burden of illness and unmet needs
in patients with CKD as they decide either not to pursue
dialysis or to withdraw from RRT. As the readers will
appreciate, there are neither RCTs nor even large cohort
studies to inform these statements within the CKD popula-
tions. Analogies with oncology have been drawn and
literature from there has been used to justify the concepts
above.
Patients with advanced CKD have extensive palliative care
needs for years before death. Throughout their illness
trajectory, symptom burden is high.702–707 The number and
severity of physical and emotional symptoms are similar to
those of cancer patients hospitalized in palliative care
settings.703,708 Advanced CKD patients managed without
dialysis are equally symptomatic.706 An increasing number of
dialysis patients die after withdrawal of dialysis (10-15% in
1990, 20% in 2004), primarily due to poor QOL, representing
the second leading cause of death after CVD.
Conservative care focuses on slowing the decline in
renal function, actively managing symptoms, advance care
planning, and the provision of appropriate palliative care.
In oncology, receiving early palliative care is associated with
better QOL, fewer emergency department visits and
hospitalizations, less aggressive care at the end of life, and
surprisingly, longer survival.709 These observations
suggest that development of clinical models that integrate
appropriate palliative care, including the creation of
conservative care pathways, are likely to be hugely beneficial
and would help avoid harmful dialysis to those
patients unlikely to realize benefit. Such conservative care
programs are slowly being developed, primarily in the UK
and Canada.
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The literature describing experiences of specific programs
and symptom burden in CKD, as well as advocating for better
care, has only become more prevalent since 2005.709–716
Poor quality, hospitalized deaths began to improve for
patients dying with cancer as a result of an increasing
emphasis on palliative care teams providing attention to
symptom control, psychosocial needs, and options for
location of care. The literature suggests that current models
of palliative care for cancer patients that deinstitutionalized
health-care services have not only improved patient out-
comes and quality of care717–720 but have been cost-
neutral.721
International Relevance
All countries have people with CKD who withdraw either
voluntarily or involuntarily from dialysis services. Best care
for those patients will obviously need to respect cultural and
religious values, but would necessarily be based on the same
philosophical grounds of maintaining dignity of the in-
dividual. Appreciating the need for and articulating con-
servative care pathways overtly would be internationally
applicable.
Implications for Clinical Practice and Public Policy
There is a need to ensure appropriate access to services
and education surrounding quality care during terminal
stages of a chronic condition. There is increasing attention
to this in many societies but not in all. Appreciating the
variability in the resources required and their availability
to different groups of patients is important for implementa-
tion. Furthermore, involvement of religious and cultural
leaders in recognition of these care practices can be enhanced
if they are overtly recognized as part of the care continuum.
There is a need for robust assessment of best practices in
CKD and other chronic conditions so that we may provide
best care throughout the continuum of life. Researchers
around the world are actively pursuing this so that we may
have better tools, programs, and ultimately, better outcomes
for our patients.
Pediatric Consideration
Despite the lack of published evidence, there is no reason
to believe that children and families faced with the need
to consider conservative care or a palliative approach to
their impending ESRD would not benefit from all of the
above recommendations. It would seem reasonable for
pediatric nephrology centers to liaise with their pediatric
oncology or palliative care teams, ethicists, and pastoral care
providers to assist them in developing, defining, and/or
identifying locally available resources for situations where a
child is not deemed a candidate for RRT prior to their
occurrence.
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